Regeneron Pharmaceuticals (REGN) Long-Term Debt Issuances (2009 - 2010)
Regeneron Pharmaceuticals' quarterly Long-Term Debt Issuances came in at $47.5 million in Q1 2010, up 157.58% quarter-over-quarter from $18.5 million in Q4 2009.
Regeneron Pharmaceuticals has reported Long-Term Debt Issuances for 2 years, with the latest figure at $47.5 million in Q1 2010.
- For the quarter ending Q1 2010, Long-Term Debt Issuances changed N/A year-over-year to $47.5 million; the trailing twelve-month figure through Dec 2010 stood at $47.5 million (changed N/A YoY), and the FY2020 full-year result was $2.0 billion, changed N/A from the prior year.
- Long-Term Debt Issuances for Q1 2010 stood at $47.5 million, up from $18.5 million in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $47.5 million in Q1 2010, with the low at $18.5 million in Q4 2009.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 2.73 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Revolution Medicines | 31.20 Bn | 31.20 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2010 | 47.54 Mn |
| Mar 31, 2010 | 47.54 Mn |
| Dec 31, 2009 | 18.46 Mn |
| Dec 31, 2009 | 18.46 Mn |